Exicure (NASDAQ:XCUR) & Legend Biotech (NASDAQ:LEGN) Head-To-Head Analysis

Legend Biotech (NASDAQ:LEGN) and Exicure (NASDAQ:XCUR) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Profitability

This table compares Legend Biotech and Exicure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-7.21%	-8.71%	-5.40%
Exicure	N/A	-237.91%	-61.98%

Valuation and Earnings

This table compares Legend Biotech and Exicure”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03 billion	3.63	-$296.80 million	($0.25)	-77.08
Exicure	$500,000.00	13.76	-$4.95 million	($1.32)	-0.80

Exicure has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Legend Biotech and Exicure, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1	5	9	0	2.53
Exicure	1	0	0	0	1.00

Legend Biotech presently has a consensus target price of $54.69, indicating a potential upside of 183.82%. Given Legend Biotech’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Legend Biotech is more favorable than Exicure.

Volatility & Risk

Legend Biotech has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Exicure has a beta of 3.64, meaning that its stock price is 264% more volatile than the S&P 500.

Institutional & Insider Ownership

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 52.8% of Exicure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Legend Biotech beats Exicure on 8 of the 13 factors compared between the two stocks.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

About Exicure

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.